FDA Approves AVLAYAH: First Hunter Syndrome Treatment to Cross Blood-Brain Barrier Revolutionary therapy overcomes 20-year treatment gap for rare genetic disease The US Food and Drug Administration has granted accelerated approval to AVLAYAH™ (tividenofusp-alfa-eknm), marking a watershed moment in rare disease treatment. This is the first FDA-approved biologic specifically designed